logo
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market View 2025 - Commercial Sponsors Have Led Clinical Trials, with ArmaGen Heading Four Trials

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market View 2025 - Commercial Sponsors Have Led Clinical Trials, with ArmaGen Heading Four Trials

Yahoo4 hours ago

Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline holds 16 promising molecules. Key insights into market trends, clinical trials, and player strategies are detailed.
Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Mucopolysaccharidosis I (MPS I) (Hurler syndrome): Market View" report has been added to ResearchAndMarkets.com's offering.This report provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis I (Hurler syndrome) Therapeutics.
In 2024, there were over 1,740 diagnosed prevalent cases across 16 countries included in the epidemiology forecast. Currently, only one FDA-approved innovator drug is available for MPS I treatment. The pipeline includes 16 molecules, with one in Phase III development.
Over the past decade, commercial sponsors have led clinical trials, with ArmaGen heading four trials. Partnerships have been a significant portion of transactions across North America, Europe, and the Asia-Pacific region during this period.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Mucopolysaccharidosis I (Hurler syndrome) Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Mucopolysaccharidosis I (Hurler syndrome) Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered: 1 Preface1.1 Contents1.2 Report Scope1.3 List of Tables and Figures1.4 Abbreviations2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market Catalysts11 Appendix11.1 Methodology11.2 Methodology - Sales Forecast11.3 Methodology - Pricing and Reimbursement11.4 Methodology - PTSR and LoA AnalysisFor more information about this report visit https://www.researchandmarkets.com/r/996790
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SAP and IBM Unit Ensnared in $800 Million Quebec IT Fiasco
SAP and IBM Unit Ensnared in $800 Million Quebec IT Fiasco

Bloomberg

time17 minutes ago

  • Bloomberg

SAP and IBM Unit Ensnared in $800 Million Quebec IT Fiasco

Software company SAP SE and an IBM Corp. subsidiary are embroiled in a C$1.1 billion ($810 million) technology boondoggle that triggered both a public inquiry and an anti-corruption investigation in Quebec. The Canadian province's Treasury Board President Sonia LeBel also ordered Quebec's procurement watchdog to conduct an 'in-depth analysis' of how the government awards technology contracts, she announced Monday. The mandate came after the ongoing inquiry revealed cost overruns, potential conflicts of interest and unexplained contracts for a bungled IT upgrade.

Broadcom's 340% Rally Has Wall Street Debating If It's Magnificent Seven Material
Broadcom's 340% Rally Has Wall Street Debating If It's Magnificent Seven Material

Bloomberg

time24 minutes ago

  • Bloomberg

Broadcom's 340% Rally Has Wall Street Debating If It's Magnificent Seven Material

For more than two years, conversations about the biggest, most important technology companies have revolved around the same seven stocks. Now, some on Wall Street are making the case that Broadcom Inc. should be part of that discussion. Relentless spending on artificial intelligence computing gear has juiced the chipmaker's revenue and profits, driving a more than 340% rally since the start of 2023 and vaulting it into an elite cohort of stocks with a market value of at least $1 trillion. Meanwhile, Tesla Inc. — one of the original so-called Magnificent Seven stocks — has tumbled 22% this year as Chief Executive Officer Elon Musk's foray into US politics sparked a backlash against the electric vehicle maker.

Euro Zone Is Still Held Back by Rising Mortgage Rates, ECB Finds
Euro Zone Is Still Held Back by Rising Mortgage Rates, ECB Finds

Bloomberg

time24 minutes ago

  • Bloomberg

Euro Zone Is Still Held Back by Rising Mortgage Rates, ECB Finds

Household consumption in the euro area will remain restrained for some time as past interest-rate hikes continue to feed through to mortgages, according to research by the European Central Bank. The impact will be felt even after the ECB lowered its deposit rate to 2% from 4% starting in June 2024, economists at the Frankfurt-based institution wrote in a paper published Wednesday. That's because fixed-rate loans taken out when inflation was low are still expiring. Borrowing costs for those that are refinanced will jump to current levels.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store